Publications

4 résultats Voir en premier : les plus pertinents | les plus récents
    • Drogues, Statistiques
    • 2012
    • Article
    • Anglais

    BACKGROUND:
    To determine the seroprevalence of hepatitis B (HBV), hepatitis C (HCV) and HIV infections in problem drug users (PDU) in Luxembourg. To measure the validity of self-reported test results provided by study participants as well as obtained through the national drug-monitoring system (RELIS).
    METHODS:
    In a cross-sectional multisite study, data were collected by voluntary, anonymous and assisted questionnaires and serological detection of antibodies and antigens. Out of 1169 contacts, 397 participants were recruited within in and out-of-treatment settings (84.2% injecting drug users; IDU).
    RESULTS:
    The prevalence of antibodies to HIV was 8/272 (2.9%; 95% CI 0.9% to 4.9%), to HCV 245/343 (71.4%; 66.6% to 76.2%), and 67/310 (21.6%; 17.1% to 26.2%) to total HBV antibodies and surface antigen (for IDU 5/202, 218/268 and 59/239, respectively). Specificity of study self-reports was very high for HBV and perfect for HCV and HIV. Sensitivity was 0.224, 0.798 and 0.800, respectively. Kappa scores provided degrees of agreement between serological tests and study self-reports of 0.89 for HIV, 0.65 for HCV and 0.25 for HBV. In contrast to simultaneous cross-sectional self-reports, secondary self-reported data (RELIS) showed high agreement for HIV and HBV infections and provided a good proxy for estimation of HCV seroprevalence.
    CONCLUSION:
    HIV testing routines in PDU should be completed at least by HBV and HCV detection given the poor validity of cross-sectional self-reports on hepatitis infections. HIV and hepatitis prevalence estimations in PDU gain by relying on multisite/setting data collection. Research should further investigate the validity of HIV and hepatitis self-reports from routine drug-monitoring systems versus cross-sectional surveys.

    Souce: Pubmed

    • Date de parution:
    • Editeur: BMJ
    • Enfance et adolescence, Drogues, Statistiques
    • 2012
    • Rapport
    • Anglais

    Enquête paneuropéenne sur l’alcool et d’autres drogues en milieu scolaire (ESPAD).

    Le nouveau rapport ESPAD fait état d’une consommation de drogues stable chez les jeunes scolarisés et d’une réduction de la «consommation épisodique excessive d’alcool», mais pas de baisse dans le nombre de jeunes fumeurs de tabac.

    Il s’agit de la cinquième vague de collecte de données conduite par le projet ESPAD, les enquêtes multinationales étant menées tous les quatre ans depuis 1995 (1). Plus de 100 000 élèves ont participé à la dernière enquête. Sur l’ensemble des pays participants, 23 étaient des États membres de l’UE.

    • Date de parution:
    • Editeur: Office des publications de l'Union européenne
    • Maladies, Santé sexuelle, Statistiques
    • 2012
    • Communiqué
    • Français

    Le Luxembourg devrait renforcer le dépistage de l'hépatite, selon un nouveau classement reprenant 30 pays européens ayant participé à l’enquête menée afin de comparer les traitements et les politiques de lutte contre l'hépatite.

    • Date de parution:
    • Editeur: Health Consumer Powerhouse
    • Statistiques, Santé mentale, Maladies
    • 2012
    • Rapport
    • Anglais

    [L'Indice Européen des Maux de Tête 2012]
    As many as 50 million Europeans suffer from headache and migraine, for many with handicapping effects. Compared to other large diseases, there lacks outcomes data to tell what are the best therapies and if prevention matters. The first Euro Headache Index (EHI) compares in what way 29 European countries address and take care of headache and migraine, by healthcare and other measures. The Netherlands comes out number 1 on good headache environment, followed by Germany, Denmark and Austria.
    The 2012 EHI looks into the following areas: Patients rights and information, Professional awareness and education, Access to healthcare, Medication/treatment and Prevention. In total there are 34 indicators for measurement.

    • Date de parution:
    • Editeur: Health Consumer Powerhouse
  • Dernière modification le 12-10-2015